EMAIL THIS PAGE TO A FRIEND

PloS one

Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A.


PMID 26295164

Abstract

CCG-1423 suppresses several pathological processes including cancer cell migration, tissue fibrosis, and the development of atherosclerotic lesions. These suppressions are caused by inhibition of myocardin-related transcription factor A (MRTF-A), which is a critical factor for epithelial-mesenchymal transition (EMT). CCG-1423 can therefore be a potent inhibitor for EMT. CCG-1423 and related compounds, CCG-100602 and CCG-203971 possess similar biological activities. Although these compounds are comprised of two stereoisomers, the differences in their biological activities remain to be assessed. To address this issue, we stereoselectively synthesized optically pure isomers of these compounds and validated their biological activities. The S-isomer of CCG-1423 rather than the R-isomer exhibited modestly but significantly higher inhibitory effects on the cellular events triggered by MRTF-A activation including serum response factor-mediated gene expression and cell migration of fibroblasts and B16F10 melanoma cells. Accordingly, the S-isomer of CCG-1423 more potently blocked the serum-induced nuclear import of MRTF-A than the R-isomer. No such difference was observed in cells treated with each of two stereoisomers of CCG-100602 or CCG-203971. We previously reported that the N-terminal basic domain (NB), which functions as a nuclear localization signal of MRTF-A, is a binding site for CCG-1423. Consistent with the biological activities of two stereoisomers of CCG-1423, docking simulation demonstrated that the S-isomer of CCG-1423 was more likely to bind to NB than the R-isomer. This is a first report demonstrating the stereospecific biological activities of CCG-1423.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

277762
(+)-Methyl D-lactate, 98%, optical purity ee: 96% (GLC)
C4H8O3
89763
(R)-Boc-Nip-OH, ≥97.0% (HPLC)
C11H19NO4
495018
1-(tert-Butoxycarbonyl)-3-piperidinecarboxylic acid, 98%
C11H19NO4
SAB4300397
Anti-MYOD1 (Ab-200) antibody produced in rabbit, affinity isolated antibody
SAB2105139
Anti-MYOD1 antibody produced in rabbit, affinity isolated antibody
SAB1410813
Anti-MYOD1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB2501587
Anti-MYOG (C-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA038093
Anti-MYOG antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1410814
Anti-MYOG antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
424846
Benzyl (S)-(−)-lactate, technical grade, 90%
C10H12O3
M6190 Monoclonal Anti-MYOD1 antibody produced in mouse, clone 5.2F, purified immunoglobulin, buffered aqueous solution
WH0004654M1
Monoclonal Anti-MYOD1 antibody produced in mouse, clone 1A7, purified immunoglobulin, buffered aqueous solution
SAB5300415
Monoclonal Anti-MYOD1 antibody produced in mouse, clone 1C8, ascites fluid
WH0004656M1
Monoclonal Anti-MYOG antibody produced in mouse, clone 2B7, purified immunoglobulin, buffered aqueous solution
SAB1404106
Monoclonal Anti-MYOG antibody produced in mouse, clone 2E7, purified immunoglobulin, buffered aqueous solution
SAB1409339
Monoclonal Anti-MYOG antibody produced in mouse, clone 3E3, purified immunoglobulin, buffered aqueous solution
M5815 Monoclonal Anti-Myogenin antibody produced in mouse, clone F12B, purified immunoglobulin, buffered aqueous solution